



European Medicines Agency

Doc. Ref. EMEA/427084/2009
P/128/2009

EUROPEAN MEDICINES AGENCY DECISION

of 14 July 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for rituximab (Mabthera) (EMA-000308-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

EUROPEAN MEDICINES AGENCY DECISION

of 14 July 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for rituximab (Mabthera) (EMEA-000308-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Roche Products Ltd. on 26 June 2008 under Article 16(1) also requesting a waiver under Article 13 of said Regulation,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 May 2009, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a Paediatric Investigation Plan and on the granting of a waiver,
- (2) It is therefore appropriate to adopt a Decision granting a Paediatric Investigation Plan.
- (3) It is therefore appropriate to adopt a Decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1

² OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for rituximab (Mabthera), concentrate for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed .

Article 2

A waiver for rituximab (Mabthera), concentrate for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Roche Products Ltd., 6 Falcon Way, Shire Park, AL7 1TW, Welwyn Garden City, United Kingdom.

Done at London, 14 July 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)



European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/301784/2009
EMEA-000308-PIP01-08

OPINION OF THE PAEDIATRIC COMMITTEE ON THE AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN AND A WAIVER

Scope of the application

Active substance(s):

Rituximab

Invented name:

Mabthera

Condition(s):

Autoimmune arthritis

Diffuse large B-cell lymphoma

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Roche Products Ltd.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Roche Products Ltd. submitted for agreement to the EMA on 26 June 2008 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 31 July 2008.

Supplementary information was provided by the applicant on 20 March 2009.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix.

London, 29 May 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

Autoimmune arthritis
Diffuse large B-cell lymphoma

B. WAIVER

- **Condition**

Autoimmune arthritis

The waiver applies to:

All subsets of the paediatric population from birth to less than 18 years of age for concentrate for solution for infusion for intravenous use,

on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

- **Condition**

Diffuse large B-cell lymphoma

The waiver applies to:

Children from birth to less than 6 months of age for concentrate for solution for infusion for intravenous use,

on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Diffuse large B-cell lymphoma

- **Proposed PIP indication**

Treatment of mature B-cell malignancies, that is, diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukaemia

- **Subset(s) of the paediatric population concerned by the paediatric development**

From 6 months to less than 18 years

- **Formulation(s)**

Concentrate for solution for infusion for intravenous use

- **Studies**

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	1	Open-label, randomised, controlled, parallel-group, multicentre, assessment-blinded trial to evaluate the pharmacokinetics, pharmacodynamics, safety and efficacy of rituximab add-on to standard chemotherapy in children from 6 months to less than 18 years of age with advanced stage with B-cell lymphoma (excluding primary mediastinal B-cell lymphoma), Burkitt and Burkitt-like lymphoma/leukaemia

Measures to address long term follow-up of potential safety issues in relation to paediatric use	Yes
Date of completion of the paediatric investigation plan	By October 2014
Deferral for some or all studies contained in the paediatric investigation plan	No

ANNEX II
INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

<u>EU Number</u>	<u>Invented name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of Administration</u>	<u>Packaging</u>	<u>Content (concentration)</u>	<u>Packaging size</u>
EU/1/98/067/001	Mabthera	100 mg	Concentrate for solution for infusion	Intravenous use	vial (glass)	10 ml (10 mg/ml)	2 vials
EU/1/98/067/002	Mabthera	500 mg	Concentrate for solution for infusion	Intravenous use	vial (glass)	50 ml (10 mg/ml)	1 vial